Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization

被引:57
|
作者
Beckers, NGM
Laven, JSE
Eijkemans, MJC
Fauser, BCJM
机构
[1] Erasmus Univ, Med Ctr, Div Reprod Med, Dept Obstet & Gynaecol, NL-3015 GD Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Dept Publ Hlth, NL-3015 GD Rotterdam, Netherlands
关键词
endocrine profiles; GnRHa; IVF protocols;
D O I
10.1093/humrep/15.1.43
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Gonadotrophin-releasing hormone agonists (GnRHa) are widely used in in-vitro fertilization (IVF) for the prevention of a premature rise in luteinizing hormone (LH) concentrations. However, the administration of GnRHa during the follicular phase may also impair subsequent luteal function due to retarded recovery of pituitary gonadotrophin secretion. Therefore, luteal supplementation is generally applied. The present study was designed to determine whether a premature LH surge would still be prevented after early cessation of GnRHa during ovarian stimulation and whether subsequent luteal phase LH production would be sufficient to support progesterone synthesis by the corpus luteum, Sixty patients mere randomized for three groups: (i) A long GnRHa/human menopausal gonadotrophin (HMG) protocol with luteal support by repeated human chorionic gonadotrophin (HCG) (II = 20), (ii) early follicular phase cessation of GnRHa without luteal support (n = 20), and (iii) a long GnRHa protocol without luteal support (rt 20), Frequent ultrasound and blood sampling was performed during the entire IVF cycle. Forty normoovulatory women served as controls, No premature LH surges were found after early cessation of GnRHa, In this group, some pituitary recovery occurred during the late luteal phase, but this did not affect corpus luteum function. Progesterone concentrations mere shown to be dependent on disappearance of the pre-ovulatory bolus of HCG, Pregnancies occurred in all three groups. In conclusion, early follicular phase cessation of GnRHa is still effective in the prevention of a premature rise in LH, Although some pituitary recovery was observed thereafter, corpus luteum function is still abnormal due to early luteolysis.
引用
收藏
页码:43 / 49
页数:7
相关论文
共 50 条
  • [1] Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?
    Lin, Y
    Kahn, JA
    Hillensjö, T
    [J]. HUMAN REPRODUCTION, 1999, 14 (04) : 885 - 888
  • [2] Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: effect on ovarian response and in-vitro fertilization outcome
    Elgendy, M
    Afnan, M
    Holder, R
    Lashen, H
    Afifi, Y
    Lenton, W
    Sharif, K
    [J]. HUMAN REPRODUCTION, 1998, 13 (09) : 2382 - 2385
  • [3] Ovarian reserve test with the gonadotrophin-releasing hormone agonist buserelin: Correlation with in-vitro fertilization outcome
    GaltierDereure, F
    DeBouard, V
    Picot, MC
    Vergnes, C
    Humeau, C
    Bringer, J
    Hedon, B
    [J]. HUMAN REPRODUCTION, 1996, 11 (07) : 1393 - 1398
  • [4] Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF
    Fujii, S
    Sato, S
    Fukui, A
    Kimura, H
    Kasai, G
    Saito, Y
    [J]. HUMAN REPRODUCTION, 2001, 16 (08) : 1671 - 1675
  • [5] Influence of gonadotrophin-releasing hormone agonist total dose in the ovarian stimulation in the long down-regulation protocol for in-vitro fertilization
    Alvarez, C
    Cremades, N
    Blasco, N
    Bernabeu, R
    [J]. HUMAN REPRODUCTION, 1997, 12 (11) : 2366 - 2369
  • [6] Endometrial ultrasonography as a predictor of pregnancy in an in-vitro fertilization programme after ovarian stimulation and gonadotrophin-releasing hormone and gonadotrophins
    Oliveira, JBA
    Baruffi, RLR
    Mauri, AL
    Petersen, CG
    Borges, MC
    Franco, JG
    [J]. HUMAN REPRODUCTION, 1997, 12 (11) : 2515 - 2518
  • [7] Ovarian stimulation for in-vitro fertilization intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists
    Felberbaum, R
    Diedrich, K
    [J]. HUMAN REPRODUCTION, 1999, 14 : 207 - 221
  • [8] Consequences on gonadotrophin secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for in-vitro fertilization
    Cedrin-Durnerin, I
    Bidart, JM
    Robert, P
    Wolf, JP
    Uzan, M
    Hugues, JN
    [J]. HUMAN REPRODUCTION, 2000, 15 (05) : 1009 - 1014
  • [9] High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization
    de Jong, D
    Macklon, NS
    Mannaerts, BMJL
    Bennink, HJTC
    Fauser, BCJM
    [J]. HUMAN REPRODUCTION, 1998, 13 (03) : 573 - 575
  • [10] Total dose of gonadotrophin-releasing hormone agonist: factors affecting it and its effect on in-vitro fertilization outcome
    Lashen, H
    Ledger, W
    Lopez-Bernal, A
    Barlow, D
    [J]. HUMAN REPRODUCTION, 1998, 13 : 184 - 184